NEWCELX LTD

NCELNASDAQ

🏆 #3665 by market capEarnings Sep 2US Equity

$3.19▼ $0.06 (−1.85%)

Market closed · at close

1h—

24h▼ 1.9%

7d▼ 7.4%

14d▼ 9.4%

30d▼ 19.7%

1y▼ 85.0%

🏦Market Cap

$17M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $3.15 – $3.21
52-Week Range: $1.83 – $28.03
Volume: $1.65B
Avg Volume: $2.01B
Shares Outstanding: 5.3M
Next Earnings: Oct 20, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $431,979
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-6.38
Dividend Yield: —

Why Investors Own NCEL

✓High-growth profile — revenue up +20.8% YoY with expanding US Equity exposure.
✓Healthy economics — 27% gross margin and 9% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2M▲ +18.1% YoY

Gross Margin (TTM)

26.8%▲ +4.4% YoY

Operating Income (TTM)

$393,047▲ +18.1% YoY

Free Cash Flow (TTM)

$149,978▲ +18.1% YoY

About NEWCELX LTD

NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.

🦦